Virus Outbreak: Medigen to begin phase 2 vaccine candidate trialsBy Kao Shih-ching / Staff reporterMedigen Vaccine Biologics Corp (高端疫苗) on Wednesday said it plans to begin phase 2 clinical trials next week for its COVID-19 vaccine candidate and expects to apply by the end of June for emergency use authorization for the drug. The company received NT$1.7 million in government subsidies for its phase 1 trials and would receive another NT$300 million for its phase 2 trials. Hsieh said that he is confident about the phase 2 clinical trials, as Medigen’s vaccine candidate showed good immunogenicity in the phase 1 trials and no participants showed any serious adverse reactions or fever. Medigen is thus far the only company in Taiwan to proceed to phase 2 clinical trials for a COVID-19 vaccine. It would be given access to a government Web site that has recruited more than 200,000 volunteers for domestic COVID-19 vaccine trials.

Source: Taipei Times January 07, 2021 15:56 UTC